Evidence map›Paper›PMID 30157683›Full record

Trial reportCNS oncology2018

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4

Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank Pk Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen and 5 more

Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 8 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 8 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Immunotherapy in Glioblastoma: An Overview of Current Status.Clinical pharmacology : advances and applications · 2025
    Review
  16. Article
  17. Review
  18. Revealing the role of SPP1Cell & bioscience · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Daniela A BotaDepartment of Neurology, University of California Irvine, Irvine, CA 92868, USA.
Jinah ChungChao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92868, USA.
Manisha DandekarChao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92868, USA.
Jose A CarrilloDepartment of Neurology, University of California Irvine, Irvine, CA 92868, USA.
Xiao-Tang KongDepartment of Neurology, University of California Irvine, Irvine, CA 92868, USA.
Beverly D FuDepartment of Neurology, University of California Irvine, Irvine, CA 92868, USA.
Frank Pk HsuDepartment of Neurological Surgery, University of California Irvine, Irvine, CA 92868, USA.
Axel H SchönthalDepartment of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Florence M HofmanDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Thomas C ChenDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Raphael ZidovetzkiCell Biology & Neuroscience, University of California, Riverside, CA 92507, USA.
Chrystel PrettoEpitopoietic Research Corporation, Gembloux, 5032 Isnes, Belgium.
Ankie StrikDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Virgil Ejc SchijnsEpitopoietic Research Corporation, Gembloux, 5032 Isnes, Belgium.
Apostolos StathopoulosEpitopoietic Research Corporation, Gembloux, 5032 Isnes, Belgium.
University of California, Irvine · USUniversity of Southern California · USNeurological Surgery · USWageningen University & Research · NLUniversity of California, Riverside · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

aimERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.

methodsIn this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine

conclusionThe addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.

Indexed as

ImmunomodulationAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain NeoplasmsCD4-Positive T-LymphocytesCyclophosphamideDouble-Blind MethodFemaleGlioblastomaGranulocyte-Macrophage Colony-Stimulating FactorHumansKaplan-Meier EstimateMaleMiddle AgedAntineoplastic Agents, ImmunologicalBevacizumabCyclophosphamideGranulocyte-Macrophage Colony-Stimulating FactorallogeneicautologousbevacizumabCD4+ T lymphocyteERC1671GBMGBM vaccineglioma surgeryimmunotherapy

Identifiers

PMID30157683
PMCPMC6200061
OpenAlexW2889092098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.